Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients


Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical responses to available therapies remained variable and unpredictable, making it difficult to select patients who would benefit from these types of treatments. An international team of researchers led by Jos Jonkers, group leader at the Netherlands Cancer Institute and Oncode Investigator, has now elucidated the mechanism behind this variation in treatment response.

Their research – published today in Nature – offers new opportunities to improve diagnostics and targeted therapy for many cancer patients. The results highlight the importance of studying the functional consequences of genetic changes in tumors.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.